Kengrexal

Cangrelor, the active ingredient in Kengrexal, is a P2Y12 receptor antagonist presented as an intravenous solution for intravenous use. It provides periprocedural antiplatelet therapy for patients undergoing percutaneous coronary intervention (PCI) and serves as an adjunct to anticoagulation in acute coronary syndrome patients undergoing PCI.

GNH USA supplies Kengrexal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kengrexal is a P2Y12 receptor antagonist used in the management of coronary artery disease interventions.

- Percutaneous coronary intervention (PCI): provides rapid, reversible platelet inhibition during the procedure to reduce thrombotic complications. - Acute coronary syndrome (ACS) undergoing PCI: serves as an adjunct to anticoagulation to lower the risk of procedural myocardial infarction. - Cardiac catheterization: ensures antiplatelet coverage during diagnostic and therapeutic catheter‑based procedures.

Kengrexal may cause a range of adverse reactions, most of which are related to its antiplatelet activity.

Common Side Effects: - Bleeding: bruising, epistaxis, gastrointestinal hemorrhage. - Dyspnea: shortness of breath during infusion. - Infusion site reactions: pain, erythema, or phlebitis.

Serious or Rare Side Effects: - Severe hemorrhage: intracranial or life‑threatening bleeding. - Thrombocytopenia: marked reduction in platelet count. - Anaphylaxis: acute allergic reaction with hypotension and airway compromise. - Cardiac arrest: rare but potentially fatal cardiac events. - Severe arrhythmias: ventricular tachycardia or fibrillation.

When using Kengrexal, clinicians should observe several safety measures.

- Monitor bleeding: assess patients frequently for signs of hemorrhage. - Adjust for renal impairment: consider reduced clearance in patients with severe kidney dysfunction. - Avoid in active severe bleeding: contraindicated in patients with ongoing major bleeding. - Use caution with concomitant anticoagulants: increased risk of bleeding when combined with heparin, warfarin, or direct oral anticoagulants. - Discontinue before surgery: stop infusion at least one hour prior to invasive procedures. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kengrexal can interact with other agents that affect hemostasis.

Major Interactions (Avoid): - Concurrent potent antiplatelet agents (e.g., clopidogrel, ticagrelor): may cause excessive bleeding. - Strong anticoagulants (e.g., unfractionated heparin, warfarin, direct oral anticoagulants): increase risk of severe hemorrhage.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive gastrointestinal bleeding risk. - Glycoprotein IIb/IIIa inhibitors: may enhance antiplatelet effect and bleeding. - Fibrinolytic therapy: combined use can lead to heightened hemorrhagic complications.